2012-12-17 06:52:26 - Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, has been issued a patent by the United States Patent and Trademark Office (USPTO).
Geneva, Switzerland and Archamps, France, December 17, 2012 – Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 12/532,336, titled "pyrazolo pyridine derivatives as NADPH oxidase inhibitors". The application includes composition of matters claims on the pyrazolopyridine chemical series and covers intellectual property on Genkyotex's most advanced product candidate, the small molecule GKT137831, as well as claims covering the use of GKT137831 and an earlier compound, GKT136901, in a large number of clinical applications.
“This issued U.S. patent demonstrates the value of the Genkyotex proprietary and unique NADPH oxidase (NOX) inhibitor discovery platform and represents a
significant step towards the goal of strengthening our intellectual property portfolio said Ursula Ney, Genkyotex's Chief Executive Officer. “We recently presented the excellent safety and pharmacokinetic data from the phase I studies of our lead candidate GKT137831 and are planning to file for Phase II in diabetic nephropathy in the coming months’
The issuance of this patent, together with the patent granted last month for a tetrahydroindole chemical series, is evidence of Genkyotex's dedication to implementing an effective, long-term patent strategy and provides the company with broad protection until 2029 for pyrazolopyridine derivatives and their use in numerous clinical indications. This application is part of an expanding patent portfolio for Genkyotex, with 2 patent applications now either issued or allowed with the USPTO and over 7 additional applications pending in the United States. Genkyotex is also pursuing patent applications related to the pyrazolopyridine chemicals series and its front runner molecule GKT137831 in multiple jurisdictions outside the United States.
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. Genkyotex was founded in 2006 by scientists from Switzerland, the USA and Japan, with backing from Geneva incubator Eclosion. A CHF25 million extension of the Series C investment was closed in July 2012, with existing investors, Eclosion, Edmond de Rothschild Investment Partners, Vesalius BioCapital and MP Healthcare Venture Management all reinvesting. Further information can be found at: www.genkyotex.com.
For further information, contact:
Dr. Ursula Ney Mike Sinclair
CEO, Genkyotex Halsin Partners
Tel: +41 22 880 1025 Tel: +44 20 7318 2955
Mo: +44 7900 898 708 Mo: +44 7968 022075